구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
경쟁 포지션: Competes with Epkinly on schedule and route; fixed duration is its main claim.
기전. Crosslinks CD20 on malignant B cells with CD3 on T cells; the 2:1 geometry stabilizes the synapse and drives T-cell activation and B-cell lysis.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
CD20 × CD3
Relapsed or refractory diffuse large B-cell lymphoma
US, EU, JP
Approved
columvi · glofitamab · Columvi · RO7082859 · glofitamab-gxbm
2026-09-10
Data Confidence · High
Development Signal · Established
2:1 bispecific T-cell engager
Two CD20 Fab arms and one CD3 arm on a silenced IgG1 backbone
Bivalent CD20 binding increases avidity; obinutuzumab pretreatment debulks circulating B cells to blunt first-dose CRS.
구조화 데이터
Bivalent CD20 binding increases avidity; obinutuzumab pretreatment debulks circulating B cells to blunt first-dose CRS.
CD20 loss after prior anti-CD20 therapy and T-cell exhaustion.
2:1 bispecific T-cell engager
CD20 × CD3 · CD20 expression; ctDNA clearance investigational.
CRS mitigation via pretreatment and step-up; tumor flare and infection monitoring
Competes with Epkinly on schedule and route; fixed duration is its main claim.
R/R DLBCL or large B-cell lymphoma from follicular lymphoma after ≥2 prior lines
3L+
IV with obinutuzumab pretreatment and step-up dosing
q3w for a fixed 12 cycles
ORR ~56%, CR ~43%
CRS mitigation via pretreatment and step-up; tumor flare and infection monitoring
Competes with Epkinly on schedule and route; fixed duration is its main claim.
Crosslinks CD20 on malignant B cells with CD3 on T cells; the 2:1 geometry stabilizes the synapse and drives T-cell activation and B-cell lysis.
T-cell expansion and cytokine release concentrated in cycle 1.
Redirected T-cell killing of CD20+ B cells.
CD20 expression; ctDNA clearance investigational.
CD20 loss after prior anti-CD20 therapy and T-cell exhaustion.
구조화 데이터
ratumor T cells from preclinical tumor model
Human, cynomolgus
~1–2 weeks
B-cell depletion, cytokine profile, PET-CR
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA accelerated approval (3L+ DLBCL)
APPROVAL · 2023년 6월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
경쟁 포지션: Competes with Epkinly on schedule and route; fixed duration is its main claim.
기전. Crosslinks CD20 on malignant B cells with CD3 on T cells; the 2:1 geometry stabilizes the synapse and drives T-cell activation and B-cell lysis.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
CD20 × CD3
Relapsed or refractory diffuse large B-cell lymphoma
US, EU, JP
Approved
columvi · glofitamab · Columvi · RO7082859 · glofitamab-gxbm
2026-09-10
Data Confidence · High
Development Signal · Established
2:1 bispecific T-cell engager
Two CD20 Fab arms and one CD3 arm on a silenced IgG1 backbone
Bivalent CD20 binding increases avidity; obinutuzumab pretreatment debulks circulating B cells to blunt first-dose CRS.
구조화 데이터
Bivalent CD20 binding increases avidity; obinutuzumab pretreatment debulks circulating B cells to blunt first-dose CRS.
CD20 loss after prior anti-CD20 therapy and T-cell exhaustion.
2:1 bispecific T-cell engager
CD20 × CD3 · CD20 expression; ctDNA clearance investigational.
CRS mitigation via pretreatment and step-up; tumor flare and infection monitoring
Competes with Epkinly on schedule and route; fixed duration is its main claim.
R/R DLBCL or large B-cell lymphoma from follicular lymphoma after ≥2 prior lines
3L+
IV with obinutuzumab pretreatment and step-up dosing
q3w for a fixed 12 cycles
ORR ~56%, CR ~43%
CRS mitigation via pretreatment and step-up; tumor flare and infection monitoring
Competes with Epkinly on schedule and route; fixed duration is its main claim.
Crosslinks CD20 on malignant B cells with CD3 on T cells; the 2:1 geometry stabilizes the synapse and drives T-cell activation and B-cell lysis.
T-cell expansion and cytokine release concentrated in cycle 1.
Redirected T-cell killing of CD20+ B cells.
CD20 expression; ctDNA clearance investigational.
CD20 loss after prior anti-CD20 therapy and T-cell exhaustion.
구조화 데이터
ratumor T cells from preclinical tumor model
Human, cynomolgus
~1–2 weeks
B-cell depletion, cytokine profile, PET-CR
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA accelerated approval (3L+ DLBCL)
APPROVAL · 2023년 6월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.